^
Association details:
| Biomarker: | PALB2 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | pidnarulex (CX-5461) (RNA polymerase 1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Senhwa’s Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations
Published date:
01/24/2022
Excerpt:
Senhwa Biosciences, Inc....announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for Pidnarulex, a first-in-class G-quadruplex stabilizer, for the treatment of patients with breast and ovarian cancers BRCA1/2, PALB2, or other HRD mutations.
